Biopharma and CRO veteran Marshall nabs inflammatory disorder role at Worldwide

Pushpin showing North Carolina on a map
North Carolina-based Worldwide Clinical Trials takes on Philippa Marshall for her immunology experience. (Getty/Creative RF)

Thirty-year life science veteran Philippa Marshall, M.D., has been hired as Worldwide Clinical Trials’ new vice president for scientific solutions in immune-mediated inflammatory disorders.

The North Carolina-based CRO takes on Marshall after a career spanning three decades, with stints at GlaxoSmithKline, Novo Nordisk, inVentiv Health and, more recently, PPD, where her roles focused predominately on immunology, rare diseases and medicines for kids.

“Dr. Marshall brings an unwavering dedication to advancing science and medicine and nearly three decades of therapeutic expertise to our expanding Scientific Solutions team,” said Peter Benton, president and chief operating officer of WCT.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Worldwide Clinical inks partnership deal with Deep Lens

“She will play a key role in providing the innovative insight our customers have come to expect from a CRO of our size. There’s really no substitute for the uncommon combination of world-class therapeutic expertise, global operations and personalized attention our team delivers," Benton added.

Suggested Articles

The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.

On the heels of a $120 million verdict issued last month, J&J was ordered by a Philadelphia jury to pay $80 million to a woman whose mesh eroded.

Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.